While adult therapy guidelines recommend the addition of trastuzumab in HER2-positive advanced gastric cancer (prevalence 10–20%), none of the tumor samples studied in the STEP cohort (n = 6) had HER2/neu overexpression [23,46]. This evidence concerns the gene ERBB2 and gastric cancer.